Search

Your search keyword '"Gold K"' showing total 265 results

Search Constraints

Start Over You searched for: Author "Gold K" Remove constraint Author: "Gold K"
265 results on '"Gold K"'

Search Results

3. Evidence of microscopic effects in fragment mass distribution in heavy ion induced fusion-fission reactions

5. Making stillbirths visible: a systematic review of globally reported causes of stillbirth

8. OA03.04 Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC

11. HCN and HCO + in Planetary Nebulae: The Next Level.

13. LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC

14. 975TiP Phase Ib trial of ABBV-368 + tilsotolimod in combination with nab-paclitaxel and/or budigalimab (ABBV-181) in patients with recurrent/metastatic head and neck squamous cell carcinoma

18. Retaining nurses via organizational support and pay during COVID‐19 pandemic: The moderating effect between intrinsic and extrinsic incentives

22. Calibration of the TOPEX altimeter using a GPS buoy

23. Five Years Of Family Medicine Undergraduate Education In Ghana: A Wake-Up Call!

24. Parents’ and healthcare professionals’ experiences of care after stillbirth in low‐ and middle‐income countries: a systematic review and meta‐summary

25. Codeless GPS Applications to Multi-Path: CGAMP

26. Making stillbirths visible: a systematic review of globally reported causes of stillbirth

27. Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in a phase 1/2 trial

28. Parents' and healthcare professionals' experiences of care after stillbirth in low- and middle-income countries: a systematic review and meta-summary.

35. Das Zentrum für Lehre in Regensburg – Vernetzung medizindidaktischer Expertise zur Verbesserung der medizinischen Ausbildung

36. 3061 Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK+ NSCLC and intracranial metastases in a Phase 1/2 Study

37. Phase 1/2 Study of Ap26113 in Patients (PTS) with Advanced Malignancies, Including Anaplastic Lymphoma Kinase (ALK)–Positive Non-Small Cell Lung Cancer (NSCLC): Analysis of Safety and Efficacy at Selected Phase 2 Doses

39. Alk Inhibitor Ap26113 in Patients with Advanced Malignancies, Including Alk+ Non-Small Cell Lung Cancer (Nsclc): Updated Efficacy and Safety Data

41. Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methods

42. Maternal complications associated with stillbirth delivery: A cross-sectional analysis.

45. Lectures

46. Biologic risk model for recurrence in resected early-stage non-small cell lung cancer (ES NSCLC).

48. Non-Oral Poster 24

Catalog

Books, media, physical & digital resources